MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Opioid dependence, uncomplicated (F11.20)

HealthDay 25 June at 03.04 PM

ADHD Meds May Help Control Opioid Use Disorder in Pregnancy

Psychostimulants may help opioid use disorder (OUD) outcomes in pregnant women, according to a study published online June 11 in Nature Mental Health.Kevin Y. Xu, M.D., M.P.H., from the Washington University School of Medicine in St. Louis, and colleagues used U.S. multistate administrative data to examine the risks and benef

HealthDay 20 June at 03.52 PM

About One-Third of Mental Health Facilities Offer Meds for Opioid Addiction

About one-third of community outpatient mental health treatment facilities (MHTFs) offer medications for opioid use disorder (MOUD), according to a study published online June 18 in JAMA Network Open.Jonathan Cantor, Ph.D., from RAND in Santa Monica, California, and colleagues quantified the availability of MOUD at community outpatien

HealthDay 17 June at 04.09 PM

Few Receive Meds for Opioid Use Disorder After Nonfatal Overdose

In the 12 months after a nonfatal overdose, few Medicare beneficiaries receive medications for opioid use disorder (MOUD) or fill a naloxone prescription, according to a study published online June 17 in JAMA Internal Medicine.Christopher M. Jones, Pharm.D., Dr.P.H., from the Substance Abuse and Mental Health Services Administration in

HealthDay 25 January at 04.44 PM

Congenital Malformation Risk Lower With Buprenorphine Versus Methadone

The risk for congenital malformations is lower in association with buprenorphine versus methadone for opioid use disorder in pregnancy, according to a study published online Jan. 22 in JAMA Internal Medicine.Elizabeth A. Suarez, Ph.D., M.P.H., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues compa

HealthDay 25 January at 03.14 PM

FDA Issues Another Warning on Tianeptine Products, Which Can Cause Seizures and Death

Reiterating a warning first issued in November, the U.S. Food and Drug Administration is urging Americans to stay away from supplements containing tianeptine, known on the street as "gas station heroin."The supplements, sold under the brand name Neptune's Fix online and at gas stations and convenience stores, can cause seizures, unconsciousnes

HealthDay 20 January at 12.01 AM

Study IDs Risks to Offspring Associated With Prenatal Opioid Exposure

Prenatal opioid exposure (POE) is associated with an increased risk for infection, eczema and dermatitis, and asthma in offspring, but it is not linked to allergies or anaphylaxis, according to a study published online Jan. 17 in JAMA Network Open.Erin Kelty, Ph.D., from the University of Western Australia in Crawley, and colleagues com

HealthDay 17 January at 11.52 PM

New Rx for Schedule-II Stimulants for ADHD Increased During Pandemic

Incident use of common behavioral health medications remained relatively stable during the COVID-19 pandemic, with the exception of those for attention-deficit/hyperactivity disorder (ADHD), according to a study published online Jan. 10 in JAMA Psychiatry.Grace Chai, Pharm.D., M.P.H., from the U.S. Food and Drug Administration i

HealthDay 16 January at 04.49 PM

Cannabis Does Not Impact Nonmedical Opioid Use in Opioid Use Disorder

For patients receiving pharmacotherapies for opioid use disorder (OUD), cannabis use is not associated with nonmedical opioid use, according to a systematic review and meta-analysis published online Jan. 16 in the American Journal of Drug and Alcohol Abuse.Gabriel P.A. Costa, from the University of Ribeirão Preto in Brazil, and colleag

HealthDay 09 January at 05.00 PM

Access to Residential Addiction Treatment Centers for Teens Limited

For adolescents, access to U.S. residential addiction treatment centers is limited and costly, according to a study published in the January issue of Health Affairs.Caroline A. King, M.P.H., from Oregon Health & Science University in Portland, and colleagues identified 160 residential addiction treatment facilities that treated adol

HealthDay 08 January at 04.56 PM

Mindfulness-Oriented Recovery Enhancement Boosts Methadone Treatment

Telehealth-delivered mindfulness-oriented recovery enhancement (MORE) is a feasible and effective adjunct to methadone treatment (MT) for individuals with opioid use disorder (OUD) and pain, according to a study published online Dec. 7 in JAMA Psychiatry.Nina A. Cooperman, Psy.D., from Rutgers Robert Wood Johnson Medical School in P

HealthDay 08 January at 04.56 PM

Mindfulness-Oriented Recovery Enhancement Boosts Methadone Treatment

Telehealth-delivered mindfulness-oriented recovery enhancement (MORE) is a feasible and effective adjunct to methadone treatment (MT) for individuals with opioid use disorder (OUD) and pain, according to a study published online Dec. 7 in JAMA Psychiatry.Nina A. Cooperman, Psy.D., from Rutgers Robert Wood Johnson Medical School in P

HealthDay 03 January at 04.25 PM

2016 to 2020 Saw Rise in Against-Medical-Advice Discharges for Opioid Admissions

Before-medically-advised (BMA) discharges increased to one in six patients from 2016 to 2020 for admissions with opioid use disorder (OUD) and an injection-related infection, according to a research letter published in the Dec. 4 issue of the Journal of the American Medical Association.Ashish P. Thakrar, M.D., from the University

HealthDay 02 January at 11.50 PM

Personalized Protocol Cuts Opioid Prescribing After C-Section

A personalized protocol for opioid prescriptions after cesarean delivery reduces the median morphine milligram equivalents prescribed at discharge, according to a study recently published in the American Journal of Obstetrics & Gynecology.Chinonye S. Imo, M.D., from Parkland Health in Dallas, and colleagues examined whether a transi

Evalytics 22 December at 03.52 PM

FDA approves first test to help screen for risk of opioid use disorder

AvertD is an AI-powered tool that uses electronic health records to predict opioid use disorder risk, aiding early intervention and addressing the opioid crisis.

Evalytics 22 December at 02.27 PM

Could a little-known psychedelic drug treat opioid addiction? Kentucky wants to find out.

Kentucky is seeking federal approval to study ibogaine, a psychedelic drug from West Africa, as a potential treatment for opioid addiction. Ibogaine has shown promise in reducing withdrawal symptoms and cravings, presenting an alternative approach to traditional addiction treatments.

HealthDay 21 December at 11.17 PM

FDA Approves DNA Cheek Swab Test to ID Patients at High Risk for Opioid Addiction

The U.S. Food and Drug Administration has approved a first-of-its-kind test -- the AvertD test -- that uses DNA swabbed from a patient's cheek to determine if they have a combination of genetic variants associated with an elevated risk for opioid addiction.The 15 genetic variants detected by the test are involved in the brain reward pathways t

Evalytics 18 December at 05.42 PM

Could a little-known psychedelic drug treat opioid addiction? Kentucky wants to find out.

Kentucky is launching a pilot program to study the use of the psychedelic drug ibogaine as a potential treatment for opioid addiction, despite its federal illegality. Derived from a West African shrub, ibogaine shows promise in combating the opioid crisis, and this initiative seeks to assess its effectiveness and safety.

HealthDay 18 December at 04.48 PM

Opioid Agonist Therapy Use in Hospital Increased to 5.6 Percent in 2020

Among hospital encounters for opioid toxicity, opioid agonist therapy (OAT) initiation increased from 2013 to 2020, reaching 5.6 percent, according to a study published online Dec. 18 in CMAJ, the journal of the Canadian Medical Association.Tina Hu, M.D., from the University of Toronto, and colleagues conducted a retrospective, populati

HealthDay 15 November at 11.02 PM

Opioid Rx Down, but Overdoses and Deaths Up, AMA Report Shows

Opioid prescribing by physicians and other health professionals has decreased for the 13th consecutive year, down nearly 50 percent since 2012, while overdoses and deaths related to illicitly manufactured fentanyl, xylazine, and other synthetic substances continue to increase, according to the Overdose Epidemic Report 2023, released by

Evalytics 31 October at 04.46 PM

Telemedicine for Buprenorphine Initiation: Revolutionizing Opioid Use Disorder Treatment

In recent years, the healthcare industry has witnessed a transformative shift towards telemedicine. This innovative approach to healthcare delivery has proven to be not only convenient but also highly effective, especially in addressing complex issues like opioid use disorder. In this article, we will explore how telemedicine has revolutionized the initiation of buprenorphine treatment for individ